Document Detail


Treatment of primary aldosteronism: Where are we now?
MedLine Citation:
PMID:  21305359     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Primary aldosteronism (PA) is an important cause of secondary hypertension, is being increasingly diagnosed and may account for more than 10% of hypertensive patients, both in primary care and in referral centers. Aldosterone excess is associated with adverse cardiovascular, renal and metabolic effects that are in part hypertension-independent. Laparoscopic adrenalectomy remains the mainstay of treatment for unilateral forms of PA, whereas medical treatment is recommended for bilateral forms of PA. However, a favourable surgical outcome depends on several factors and many patients are not suitable for this treatment. On the other hand, surgery in patients considered to have bilateral PA may contribute to better blood pressure control. In this review, established and novel strategies for the management of different types of PA are discussed.
Authors:
Asterios Karagiannis
Related Documents :
1507079 - Effect of insole material on force and plantar pressures during walking.
17318529 - Cartilage tissue engineering and bioreactor systems for the cultivation and stimulation...
16737409 - Efficacy and mechanism of orthotic devices to unload metatarsal heads in people with di...
10998609 - Comparison of an in-shoe pressure measurement device to a force plate: concurrent valid...
21694379 - Phases of vanadium under pressure investigated from first principles.
23762189 - Mobile personal health system for ambulatory blood pressure monitoring.
2988929 - The heart and the atrial natriuretic factor.
11827679 - Old and new tools to dissect calcineurin's role in pressure-overload cardiac hypertrophy.
7759449 - Effect of digital nerve blockade on heat-induced vasoconstriction in the human finger.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Reviews in endocrine & metabolic disorders     Volume:  12     ISSN:  1573-2606     ISO Abbreviation:  Rev Endocr Metab Disord     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-05-03     Completed Date:  2011-09-01     Revised Date:  2013-11-25    
Medline Journal Info:
Nlm Unique ID:  100940588     Medline TA:  Rev Endocr Metab Disord     Country:  United States    
Other Details:
Languages:  eng     Pagination:  15-20     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenalectomy
Humans
Hyperaldosteronism / diagnosis,  drug therapy*,  surgery*
Spironolactone / analogs & derivatives,  therapeutic use
Chemical
Reg. No./Substance:
27O7W4T232/Spironolactone; 6995V82D0B/eplerenone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Primary aldosteronism: A Japanese perspective.
Next Document:  Viability of cryopreserved human skin allografts: effects of transport media and cryoprotectant.